ASX-listed health and wellness products company Bioxyne has launched online healthcare business BLS Clinics with technology partner InstantScripts.
The move comes after Bioxyne completed the acquisition of Breathe Life Sciences (BLS) in May, with BLS co-founder and CEO Sam Watson and COO Jason Hine joining the board.
Bioxyne acquired 100% of BLS through a share deal, with BLS shareholders now owning 66% of the company.
BLS Clinics is an online telehealth platform specialising in plant-based healthcare consultations for patients suffering from chronic health conditions.
Watson said: “BLS Clinics allows patients to access alternative medicines to treat chronic health conditions through a delivery system that is safe and regulated.
“Our mission is to democratise healthcare and pharma to be a global leader in the manufacture and supply of novel medicines, healthcare and health-tech solutions… and to empower patients with advanced technology for screening, access, suitability, and treatment.”
BLS holds Australian licences to import, export, wholesale and manufacture Schedule 3, 4 and 8 medicines including medicinal cannabis and ketamine. It has operations in Australia, the UK, Europe, Japan, Southeast Asia, and the US.
Its international portfolio includes CBD and mushroom brand Dr Watson, available in the UK and Japan. It also supplies cannabis-derived raw materials and active pharmaceutical ingredients globally.